Jove
Visualize
Contact Us

Related Experiment Videos

Disseminated classic Kaposi's sarcoma.

I Fernández Pérez1, L Vázquez Tuñas, M Lázaro Quintela

  • 1Department of Oncology, Complejo Hospitalario Universitario de Vigo, Vigo, Spain. isauraferpe@hotmail.com

Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
|April 28, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

First-line panitumumab plus docetaxel and cisplatin in advanced gastric and gastro-oesophageal junction adenocarcinoma: results of a phase II trial.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2019
Same author

Concurrent chemoradiation for locally advanced stage III non-small cell lung cancer with cisplatin, vinorelbine, and thoracic radiotherapy: a phase II study from the Galician Lung Cancer Group.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2018
Same author

New clinical trials regulation in Spain: analysis of royal decree 1090/2015.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2016
Same author

Validation of the International Metastatic Renal-Cell Carcinoma Database Consortium (IMDC) prognostic model for first-line pazopanib in metastatic renal carcinoma: the Spanish Oncologic Genitourinary Group (SOGUG) SPAZO study.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Update on adjuvant hormonal treatment of early breast cancer.

Advances in therapy·2011
Same author

Renal primary angiosarcoma.

Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·2007
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Kaposi's sarcoma (KS) is a vascular tumor. This case study presents a rare instance of metastatic Kaposi's sarcoma in a 67-year-old woman without a confirmed immunodeficiency.

Area of Science:

  • Oncology
  • Pathology
  • Dermatology

Background:

  • Kaposi's sarcoma (KS) is a neoplastic proliferation of vascular endothelial and lymphoreticular cells.
  • Four distinct clinical and epidemiological types of KS exist: classic, endemic, iatrogenic, and epidemic (AIDS-related).
  • Clinical presentations vary, with classic KS typically affecting lower extremities, while immunodeficiency-associated KS can involve multiple organs.

Observation:

  • A 67-year-old female patient presented with metastatic Kaposi's sarcoma.
  • The patient's immunodeficiency status was unproven at the time of presentation.
  • The case highlights a less common clinical scenario for KS.

Findings:

  • The histological pattern of KS is similar across its subtypes.

Related Experiment Videos

  • Metastatic spread of KS can occur even in the absence of a clear immunodeficiency diagnosis.
  • This case underscores the importance of considering KS in metastatic presentations.
  • Implications:

    • Further investigation into the etiology of KS in non-immunocompromised individuals is warranted.
    • This case may inform diagnostic approaches for metastatic KS.
    • Understanding atypical KS presentations is crucial for effective patient management.